Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

Qure (NASDAQ:QURE) shares added ~39% in the premarket on Thursday after the Dutch biotech announced that the FDA granted ...